myboxpra/iStock via Getty Images Phase 2 follow-up data on Jazz Pharmaceuticals' ( NASDAQ: JAZZ ) zanidatamab found that the bispecific antibody led to median overall survival of 15.5 months in previously treated patients with HER2-positive biliary tract cancer. Data showed that the objective response rate was 41.
3%, the study's primary endpoint. Median duration of response, a secondary endpoint, increased by about two months to 14.9 months compared to earlier findings.
Also, median progression-free survival was maintained at 5.5 months. More on Jazz Pharmaceuticals Jazz Pharmaceuticals: Cheap But Complicated Avadel gains for a second day as analysts see it prevailing in case vs Jazz/FDA Avadel Pharma gains during hearing over dispute on FDA approval of a sleep disorder drug (update) J azz Pharmaceuticals plc (JAZZ) Q1 2024 Earnings Call Transcript Jazz Pharmaceuticals plc 2024 Q1 - Results - Earnings Call Presentation.
